Significant milestone for the Dementia with Lewy Bodies community: new DLB trials moving to Phase 3; CervoMed aligned with the FDA on a registration path for neflamapimod.
#Dementia #LewyBodyDementia #DLB #ClinicalTrials #Phase3 #Neflamapimod

Dementia drug neflamapimod shows positive phase 2b trial results - PharmaTimes CervoMed's therapy demonstrates significant improvement in patients

#AlzheimersDisease #Dementia #neflamapimod #CNSdisorders #biotech #CervoMed #dementiapatients #RewinDLBstudy #dementiawithLewybodies #DLB #ClinicalDementiaRatingSumofBoxes #CDRSB #AlzheimersDiseaseCooperativeStudy #ClinicalGlobalImpressionofChange #CGIC
pharmatimes.com/news/dementi...